Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.60 -1.8%	$1.71	$1.05 ▼ $3.56	$68.48M	2.01	1.32 million shs	361,987 shs
ANVS Annovis Bio	$1.93 +1.3%	$2.09	$1.54 ▼ $5.50	$66.70M	1.26	793,902 shs	959,192 shs
LPCN Lipocine	$2.25 -0.4%	$3.45	$1.81 ▼ $12.37	$18.54M	0.5	298,207 shs	81,665 shs
XBIT XBiotech	$2.42 -0.8%	$2.42	$2.09 ▼ $3.61	$73.79M	0.88	36,163 shs	44,014 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-1.81%	-8.94%	-14.21%	+7.95%	+48.18%
ANVS Annovis Bio	-5.46%	-11.60%	+1.60%	-29.18%	-21.28%
LPCN Lipocine	-0.88%	+1.80%	-2.16%	-77.31%	-33.53%
XBIT XBiotech	0.00%	-1.61%	-3.94%	+7.96%	-16.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.60 -1.8%	$1.71	$1.05 ▼ $3.56	$68.48M	2.01	1.32 million shs	361,987 shs
ANVS Annovis Bio	$1.93 +1.3%	$2.09	$1.54 ▼ $5.50	$66.70M	1.26	793,902 shs	959,192 shs
LPCN Lipocine	$2.25 -0.4%	$3.45	$1.81 ▼ $12.37	$18.54M	0.5	298,207 shs	81,665 shs
XBIT XBiotech	$2.42 -0.8%	$2.42	$2.09 ▼ $3.61	$73.79M	0.88	36,163 shs	44,014 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-1.81%	-8.94%	-14.21%	+7.95%	+48.18%
ANVS Annovis Bio	-5.46%	-11.60%	+1.60%	-29.18%	-21.28%
LPCN Lipocine	-0.88%	+1.80%	-2.16%	-77.31%	-33.53%
XBIT XBiotech	0.00%	-1.61%	-3.94%	+7.96%	-16.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.60	Moderate Buy	$11.67	629.17% Upside
ANVS Annovis Bio	2.25	Hold	$13.50	601.30% Upside
LPCN Lipocine	2.33	Hold	$15.00	566.67% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LPCN, XBIT, ACRV, and ANVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/8/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/29/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/27/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/24/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/14/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00
4/6/2026	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
3/27/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
3/2/2026	ACRV Acrivon Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$2.23 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.09 per share	N/A
LPCN Lipocine	$1.98M	9.36	N/A	N/A	$2.77 per share	0.81
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$2.00	N/A	N/A	N/A	N/A	-64.43%	-57.08%	8/12/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.71	N/A	N/A	N/A	N/A	-318.08%	-215.47%	N/A
LPCN Lipocine	-$9.63M	-$1.88	N/A	N/A	N/A	-571.18%	-66.70%	-59.39%	8/4/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.32	N/A	N/A	N/A	N/A	-26.10%	-25.06%	N/A

Latest LPCN, XBIT, ACRV, and ANVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2026	Q1 2026	ANVS Annovis Bio	-$0.3950	-$0.63	-$0.2350	-$0.63	N/A	N/A
5/14/2026	Q1 2026	XBIT XBiotech	$0.03	-$0.18	-$0.21	-$0.18	$7.00 million	N/A
5/13/2026	Q1 2026	ACRV Acrivon Therapeutics	-$0.49	-$0.49	N/A	-$0.49	$0.28 million	N/A
5/7/2026	Q1 2026	LPCN Lipocine	-$0.51	-$0.54	-$0.03	-$0.54	$0.16 million	$0.12 million
3/19/2026	Q4 2025	ACRV Acrivon Therapeutics	-$0.49	-$0.49	N/A	-$0.49	$0.17 million	N/A
3/13/2026	Q4 2025	ANVS Annovis Bio	-$0.3084	-$0.39	-$0.0816	-$0.39	N/A	N/A
3/13/2026	Q4 2025	XBIT XBiotech	N/A	-$0.88	N/A	-$0.88	N/A	N/A
3/10/2026	Q4 2025	LPCN Lipocine	-$0.60	-$0.34	+$0.26	-$0.34	$0.12 million	$1.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	8.98	8.98
ANVS Annovis Bio	N/A	1.27	1.27
LPCN Lipocine	N/A	9.99	9.99
XBIT XBiotech	N/A	39.03	39.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
ANVS Annovis Bio	15.83%
LPCN Lipocine	9.11%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
ANVS Annovis Bio	20.80%
LPCN Lipocine	6.35%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	42.80 million	37.71 million	Not Optionable
ANVS Annovis Bio	3	34.65 million	27.44 million	Optionable
LPCN Lipocine	10	8.24 million	7.72 million	No Data
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

LPCN, XBIT, ACRV, and ANVS Headlines

Recent News About These Companies

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech (XBIT) Projected to Post Earnings on Tuesday

May 5, 2026 | marketbeat.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 15, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 14, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, XBIT, ACRV, and ANVS Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.60 -0.03 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 +0.04 (+2.69%)

As of 04:42 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Annovis Bio NYSE:ANVS

$1.92 +0.03 (+1.32%)

Closing price 03:59 PM Eastern

Extended Trading

$1.96 +0.04 (+2.08%)

As of 04:38 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Lipocine NASDAQ:LPCN

$2.25 -0.01 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 0.00 (0.00%)

As of 04:29 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

XBiotech NASDAQ:XBIT

$2.42 -0.02 (-0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 0.00 (0.00%)

As of 04:10 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get started with MarketBeat.

Hello!

Make the most of your MarketBeat account.

75% completed. Great work!

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPCN, XBIT, ACRV, and ANVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPCN, XBIT, ACRV, and ANVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPCN, XBIT, ACRV, and ANVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, XBIT, ACRV, and ANVS Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Annovis Bio NYSE:ANVS

Lipocine NASDAQ:LPCN

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPCN, XBIT, ACRV, and ANVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPCN, XBIT, ACRV, and ANVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPCN, XBIT, ACRV, and ANVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, XBIT, ACRV, and ANVS Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Annovis Bio NYSE:ANVS

Lipocine NASDAQ:LPCN

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools